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autonomic and central nervous sytems 
and the neuromuscular junction. A 
nAChR is composed of ﬁ  ve polypeptide 
subunits (Figure 1), but there are many 
nAChR subtypes made of different 
subunit combinations, a diversity that 
helps explain why nicotine can have 
so many different physiological and 
cognitive effects. 
It is now conventional wisdom that 
acetylcholine and nicotine act at these 
receptors to alter electrochemical 
properties at a variety of synapses, 
which can in turn affect the release of 
several other neurotransmitters. This 
wisdom exists thanks in part to work 
by Lorna Role and her colleagues at 
Columbia University in New York City. 
“In 1995, we turned people’s attention 
to how nicotine works as a modulator, 
tuning synapses and increasing the gain 
on transmitter release,” Role recalls. 
Although all nAChRs are activated by 
nicotine, other drugs could be found 
or designed that affect only a subset of 
these receptor types. “If you can dissect 
out the important players with respect 
to which nicotine receptors are tuning 
[a] particular set of synapses, then that 
provides another way to potentially 
target the therapeutics.”
Nicotine and the Brain
People with depressive-spectrum 
disorders, schizophrenia, and adult 
ADHD tend to smoke heavily, which 
suggested to researchers that nicotine 
may soothe their symptoms. Common 
to all these disorders is a failure of 
attention, an inability to concentrate 
on particular stimuli and screen out 
the rest. Nicotine helps. Researchers 
at the National Institute on Drug 
Abuse have shown via functional 
magnetic resonance imaging that 
nicotine activates speciﬁ  c brain areas 
during tasks that demand attention 
(Box 1). This may be because of 
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T
here’s a cheap, common, and 
mostly safe drug, in daily use 
for centuries by hundreds of 
millions of people, that only lately has 
been investigated for its therapeutic 
potential for a long list of common ills. 
The list includes Alzheimer disease, 
Parkinson disease, depression and 
anxiety, schizophrenia, attention deﬁ  cit 
hyperactivity disorder (ADHD), and 
even pain and obesity. Why has interest 
in this potential cure-all been slow to 
develop? One reason: in its current 
forms the drug offers pharmaceutical 
companies no possibility of substantial 
proﬁ  t. Another, perhaps more 
important: the drug is reviled as the 
world’s most addictive. The drug, of 
course, is nicotine.
Nicotine is an alkaloid in the 
tobacco plant Nicotiana tabacum, 
which was smoked or chewed in the 
Americas for thousands of years before 
European invaders also succumbed 
to its pleasures and shipped it back to 
the Old World. Nicotine has always 
been regarded as medicinal and 
enjoyable at its usual low doses. Native 
Americans chewed tobacco to treat 
intestinal symptoms, and in 1560, 
Jean Nicot de Villemain sent tobacco 
seeds to the French court, claiming 
tobacco had medicinal properties and 
describing it as a panacea for many 
ailments. Higher doses are toxic, even 
lethal—which is why nicotine is used 
around the world as an insecticide. Yet 
few of the horrendous health effects 
of smoking are traceable to nicotine 
itself—cigarettes contain nearly 4,000 
other compounds that play a role. 
Until recently, nicotine research has 
been driven primarily by nicotine’s 
unparalleled power to keep people 
smoking, rather than its potential 
therapeutic uses.
Nicotine locks on to one group of 
receptors that are normally targeted 
by the neurotransmitter acetylcholine. 
Nicotinic acetylcholine receptors 
(nAChRs) are ion channels threaded 
through cell membranes. When 
activated, either by acetylcholine or 
by nicotine, they allow selected ions 
to ﬂ  ow across the cell membrane. In 
vertebrates nAChRs are all over the 
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its effects, shared with many other 
addictive drugs, on the release of 
the neurotransmitter dopamine. 
“Schizophrenia is a disorder largely 
of the dopamine system,” says John 
Dani of the Baylor College of Medicine 
in Houston, Texas. Dopamine 
signals in the brain occur in two 
modes—a kind of background trickle, 
punctuated by brief bursts. “It’s 
thought that schizophrenics have a 
hard time separating that background 
information from important bursts. 
We’ve shown that nicotine helps to 
normalize that signaling by depressing 
the background but letting the bursts 
through well,” he says. “I’ll be surprised 
if there’s not a co-therapy [to help 
schizophrenics] that takes advantage of 
nicotine systems in less than a decade.”
Nicotine may be the link between 
two genes that appear to ﬁ  gure in 
schizophrenia. Sherry Leonard and 
Robert Freedman of the University of 
Colorado in Denver, Colorado, have 
shown that expression of the gene for 
the alpha 7 neuronal nicotinic receptor 
is reduced in schizophrenics, and have 
argued that alpha 7 abnormalities lead 
to attention problems. Researchers in 
Iceland and elsewhere have shown that 
a different gene, for the growth factor 
neuregulin, also appears to ﬁ  gure in 
the disease. Neuregulin, Role and her 
colleagues have shown, 
governs the expression 
of nAChRs in neurons 
and helps to stabilize the 
synapses where they are 
found. The researchers 
are currently studying 
interactions between 
neuregulin and alpha 7, 
which Role thinks will 
prove important. 
Smokers also 
have lower rates of 
neurodegenerative 
disorders, and nicotine 
improves cognitive and 
motor functioning in 
people with Alzheimer 
disease and Parkinson 
disease. The prevailing 
hypothesis is that 
nicotine increases release 
of neurotransmitters 
depleted in those 
diseases. Dani and 
his colleagues have 
recently shown that 
acetylcholinesterase 
inhibitors—which block the 
degradation of acetylcholine and 
hence prolong its action—used to 
treat Alzheimer disease also stimulate 
dopamine release. They suspect that 
malfunctioning of the dopamine system 
may be affecting noncognitive aspects 
of dementia such as depressed mood, 
and that this might be alleviated by 
nicotine. 
Paul Newhouse and his colleagues 
at the University of Vermont in 
Burlington, Vermont, are studying 
nicotine drugs as potential therapeutic 
agents for cognitive dysfunction. 
Newhouse, a long-time nicotine 
researcher, is heading the ﬁ  rst study 
ever to examine the efﬁ  cacy and safety 
of nicotine patches for treating mild 
cognitive impairment, thought to be 
a precursor of Alzheimer disease. The 
researchers hope to see a positive effect 
on attention and learning. Newhouse 
also heads two studies of nicotinic 
stimulation in ADHD, using the patch, 
nicotine blockers, and some novel 
drugs that activate nicotine receptors. 
Nicotine and Pain
Nicotine’s salutary effects in patients 
with neurodegenerative and mental 
disorders have been studied a lot 
and are fairly well known. Two much 
newer topics of academic research are 
nicotine’s potential for pain relief and 
for treating obesity.
Nicotine itself has provided modest 
pain relief in animal studies. Although 
the analgesic effect of drugs that 
mimic acetylcholine were originally 
attributed to a different class of 
receptors, it is now clear that nAChRs 
play an important role in the control 
of pain. For instance, epibatidine, a 
drug that is extracted from the skin 
of an Ecuadorian frog and that acts 
at nAChRs, has been shown to be 
200 times more potent than morphine 
at blocking pain in animals. Current 
animal research is aimed at discovering 
just where, how, and which classes of 
nAChRs work against pain, with the 
aim of developing more selective drugs.
Meanwhile, nicotine is also being 
investigated as an analgesic in 
humans. For example, Pamela Flood, 
an anesthesiologist at Columbia, is 
investigating nicotine’s future as a 
postoperative analgesic. She recently 
completed a pilot study of 20 women 
undergoing gynecological surgery. All 
the women had access to unlimited 
morphine and also got either a single 
3-mg dose of nicotine nasal spray or a 
placebo. The placebo group had peak 
pain scores of eight out of a possible 
ten in the ﬁ  rst hour after surgery. 
Women who got nicotine averaged a 
pain score of ﬁ  ve. Despite the small 
sample size, Flood says, the results were 
highly signiﬁ  cant. “As far as I know 
this is the ﬁ  rst clinical study to use 
nicotine for analgesia, and it was much 
more successful than I ever would have 
imagined.
“The nice thing about nicotine and 
drugs like nicotine is that they have 
opposite side effects to anesthetics. 
Instead of being respiratory depressants, 
they are respiratory stimulants. Instead 
of being sedating, they increase 
alertness. So theoretically this class of 
drugs is actually the perfect thing to 
add to an opioid regimen. The fact 
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Figure 1. Schematic Illustration of an Acetylcholine Receptor 
(Illustration: Giovanni Maki)
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that they’re synergistic was a fortuitous 
thing that we had never looked at, and 
neither had anybody else.”
Nicotine and Weight Gain
Nicotine may be the most effective 
drug around for weight control. As ex-
smokers know, to their rue, one of the 
worst things about quitting cigarettes is 
putting on pounds—as much as 10% of 
body weight. “Something about being 
addicted to nicotine and then going off 
it causes massive increase in weight,” 
Role points out.
Young-Hwan Jo in Role’s lab is 
looking at a particular brain circuit 
involved in motivational behavior, 
especially feeding behavior. It is lodged 
primarily in the lateral hypothalamus 
but has projections all over the cortex, 
especially the nucleus accumbens, 
which is the center of reinforcement. 
“This is where information that has 
come in to the thalamus and the 
hypothalamus is relayed to cortical 
areas with some sense of salience 
or remembrance. It presumably is 
involved in changing perception and 
motivation for eating. It’s not, ‘I have 
to eat this,’ it’s, ‘I want to eat this,’” says 
Role. 
Jo has been comparing the synaptic 
effects of nicotine, which reduces 
appetite, to those of cannabinoids, 
which stimulate it. “Control of these 
projection neurons seems to be 
oppositely regulated by these two,” 
Role notes. “It doesn’t necessarily 
mean we’ve found the root of the 
munchies, but it at least points to 
pathways that these things have in 
common.” Jo is also examining how 
nicotine and cannabinoids modulate 
these pathways in genetically obese 
mice, and also their interactions with 
leptins. Role says tuning these pathways 
up or down might be a reasonable 
aim. “If that could be done in a 
selective fashion, maybe that could 
be introduced in appetite control. 
Certainly I see…antagonism of some of 
these pathways that nicotine activates 
or the complementary activation of 
the cannabinoid pathways as very 
important targets for therapeutics with 
respect to the anorexia that’s associated 
with chemotherapy.”
Ming Li and his colleagues at the 
University of Texas in San Antonio, 
Texas, are studying nicotine’s effects 
on weight and on expression of genes 
related to weight, and have shown 
that nicotine upregulates orexin 
and neuropeptide Y and, more 
recently, that it also regulates leptin 
signaling. All three molecules regulate 
feeding behavior controlled by the 
hypothalamus. In the weight study, 
nicotine-treated rats not only lost 
weight, they lost about 20% of their 
body fat compared to saline-treated 
controls. The researchers suggest that, 
among its other effects, nicotine alters 
fat storage. 
The University of Texas researchers 
have scoured the literature for genes 
related to nicotine, and they are 
developing microarrays to study the 
expression of these genes (Figure 3). 
While nicotine seems to affect all the 
molecules known to inﬂ  uence weight, 
Li says it’s clear the story is even more 
complex. “That’s the reason we keep 
looking at different molecules, to ﬁ  nd 
key targets involved in this regulation.” 
The ultimate hope is to develop new 
drug applications.
Dani predicts that weight control is 
likely to be one of the earliest nicotine-
based therapies. “There’s a very good 
chance that the ﬁ  rst drug is unlikely 
to be…nicotine itself, but will take 
advantage of nicotinic receptors in 
Box 1. Nicotine’s Effect 
on Attention 
Using functional magnetic resonance 
imaging, scientists at the National Institute on 
Drug Abuse provided the ﬁ  rst evidence that 
nicotine-induced enhancement of parietal 
cortex activation is associated with improved 
attention. They compared brain activity during 
a task demanding sustained attention—rapid 
visual information processing (RVIP)—with 
that during an undemanding sensorimotor 
control task (Figure 2). Group results from 
15 smokers (right) illustrate the effects of 
nicotine and placebo patches in left and right 
parietal cortex (1 and 2) and left and right 
occipital cortex (3 and 4).  Nicotine signiﬁ  cantly 
increased activation in occipital cortex during 
both the control and rapid visual information 
processing tasks, suggesting a general 
modulation of attention. In contrast, nicotine 
increased activity in the parietal cortex only 
during rapid visual information processing, 
suggesting a speciﬁ  c modulation on task 
performance. DOI: 10.1371/journal.pbio.0020404.g002
Figure 2. The Brain on Nicotine
(Image: Elliot Stein, National Institute on Drug Abuse)
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the therapy,” he says. “I know there 
are drugs now being tested by drug 
companies just for that purpose.”
Nicotine’s Future
Developing new drugs that selectively 
target speciﬁ  c subtypes of nicotine 
receptors is an expensive, albeit 
potentially lucrative, proposition. And 
therein lies a question. Will nicotine-
based therapy consist mostly of costly 
new drugs from the pharmaceutical 
industry? Or can less expensive nicotine 
products like the patch, chewing gum, 
and nasal spray—which are generally 
intended for smoking cessation but 
widely available, usually without 
prescription—ﬁ  nd their way into the 
world’s medicine cabinets? 
“It’s a little early to call whether 
nicotine will be used itself as a 
therapeutic agent or 
whether these more 
speciﬁ  c drugs that are 
being produced or 
maybe even used in 
combination with other 
drugs may be the most 
important way to go,” 
says Dani. But he doesn’t 
see the medicinal use 
of plain nicotine as very 
likely. Dani points out 
that the body’s own 
agent, acetylcholine, 
acts over milliseconds 
to activate nicotinic 
receptors, whereas 
nicotine itself stimulates 
these receptors for hours. 
That lengthy action 
means that, although 
nicotine activates 
the receptors, it then 
often turns particular 
receptor subtypes off 
again, a process called 
desensitization. “It’s hard 
to predict inside of a 
body what you’re getting. 
Am I getting an activation or am I 
turning the receptors off?”
Yet much of the work to date 
showing nicotine’s effectiveness on a 
huge range of disorders has involved 
products available at any drugstore 
and intended to help people quit 
smoking. Newhouse is using patches 
for mild cognitive impairment. Flood 
has demonstrated pain relief with 
nasal spray and will use patches in her 
next study. And Role feels that gum 
hasn’t been adequately explored for 
its therapeutic potential. Nicotine 
gum, she notes, is a better imitator 
of smoking than the patch because it 
delivers brief hits rather than a steady 
supply. She’s also uncertain whether 
natural nicotine has been studied 
enough. But Role also points out that 
nicotine has its serious problems—
addictive potential, cardiovascular 
damage, and (especially when delivered 
through the mucosa) cancer.
Dani says, “People are probably 
going to have to ﬁ  nd creative ways 
to understand which subtypes of 
nicotinic receptors they’re turning on 
and which ones they’re desensitizing. 
Maybe drug delivery methods will 
matter. Maybe subtype speciﬁ  city will 
matter. It’s less than a decade that 
we’ve known how important nicotinic 
receptors are. Now we have to move 
forward from there.”
“We’ve made an enormous amount 
of progress on understanding the 
biology of these receptor systems 
and how to target them. What has 
been trickier has been to develop an 
appropriate pharmacology that allows 
one to selectively target agents for 
particular therapeutic purposes with 
an adequate safety index,” Newhouse 
says. “But some of the drugs that are 
coming on in human trials now are very 
promising. So I’m cautiously optimistic 
that we’re on the road to developing 
some useful nicotinic therapies.”  
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